靶向PTGDS抑制系统性硬化症中与皮肤纤维化相关的促炎性成纤维细胞
本研究通过生物信息学与实验验证发现,系统性硬化症患者真皮成纤维细胞中PTGDS表达显著升高;体外过表达PTGDS上调趋化因子并增强CD4+ T细胞(尤其Th2亚群)迁移,抑制剂AT56可逆转该效应;口服AT56在博来霉素诱导小鼠模型中减轻皮肤炎症与纤维化。
要点
- SSc患者真皮成纤维细胞中PTGDS表达显著升高。
- 过表达PTGDS的成纤维细胞促进Th2细胞浸润和皮肤纤维化,AT56可逆转。
- 口服AT56在BLM诱导小鼠中减轻皮肤炎症与纤维化。
核心结论
- PTGDS诱导的促炎性成纤维细胞引起Th2细胞浸润和皮肤纤维化,抑制PTGDS可减轻皮肤炎症和纤维化,提示PTGDS是皮肤成纤维细胞促炎功能的关键调节因子并提供有前景的SSc治疗靶点。
研究设计与样本
- 研究分析SSc患者皮肤组织中PTGDS表达(生物信息学、免疫组化、RT-PCR和Western blotting验证),体外使用PTGDS过表达BJ细胞和PTGDS抑制剂AT56,并在博来霉素(BLM)诱导皮肤纤维化小鼠模型中验证靶向PTGDS的治疗效果。
主要发现
- PTGDS表达水平在SSc患者真皮成纤维细胞中显著升高。
- 体外过表达PTGDS导致皮肤成纤维细胞多种趋化因子上调,随后增强CD4+ T细胞迁移,尤其Th2亚群,用抑制剂AT56抑制PTGDS可有效逆转该效应。
- 过表达PTGDS的成纤维细胞促进Th2细胞浸润和皮肤纤维化,口服AT56在体内显著减轻BLM诱导的皮肤炎症和纤维化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immune dysregulation significantly contributes to skin fibrosis in systemic sclerosis (SSc), with pro-inflammatory fibroblasts playing a pivotal role in this process. Prostaglandin D2 synthase (PTGDS) has garnered interest due to its enriched expression in pro-inflammatory fibroblasts associated with skin fibrosis. This study aims to elucidate the role of PTGDS in skin fibrosis in SSc and evaluate its potential as a therapeutic target. METHODS: PTGDS expression in skin tissues from SSc patients was analysed through bioinformatics and validated using immunohistochemistry, RT-PCR, and Western blotting. The biological role of PTGDS in fibroblast inflammatory priming was examined using PTGDS-overexpressed BJ cells and the PTGDS inhibitor AT56 in vitro. The therapeutic effect of targeting PTGDS in skin inflammation and fibrosis was validated using a bleomycin (BLM)-induced skin fibrosis mouse model. RESULTS: PTGDS expression levels were significantly elevated in the dermal fibroblasts of SSc patients. In vitro, overexpression of PTGDS resulted in the upregulation of various chemokines in skin fibroblasts, subsequently enhancing the migration of CD4+ T cells, particularly the Th2 subset, which was effectively reversed by inhibition of PTGDS with the inhibitor AT56. PTGDS-overexpressed fibroblasts promoted Th2 cell infiltration and skin fibrosis, and oral administration of AT56 significantly attenuated BLM-induced skin inflammation and fibrosis in vivo. CONCLUSION: PTGDS-induced pro-inflammatory fibroblasts caused Th2 cell infiltration and skin fibrosis. Inhibition of PTGDS attenuated the inflammation and fibrosis in the skin. These results demonstrate that PTGDS is a critical regulator of the pro-inflammatory function of skin fibroblasts, providing a promising therapeutic target for SSc.
引用
- Fang D, Yuan X, Yi J, et al. Targeting PTGDS inhibits pro-inflammatory fibroblasts associated with skin fibrosis in systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 40478772. doi:10.1093/rheumatology/keaf276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。